Historically, developments in transdermal drug delivery have been incremental, focusing on overcoming problems associated with the barrier properties of the skin, reducing skin irritation rates and improving the aesthetics associated with passive patch systems. More-recent advances have concentrated on the development of non-passive systems to aid delivery of larger drug molecules, such as proteins and nucleotides, as the trend for discovering and designing biopharmaceuticals continues. Fundamentally, improvements in transdermal delivery will remain incremental until there is wider acceptance of this route of administration within the pharmaceutical industry. Only then will the transdermal revolution live up to its true potential.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S1359-6446(04)03180-0 | DOI Listing |
JMIR Dermatol
November 2024
Rowan-Virtua School of Osteopathic Medicine, 113 Laurel Rd, Stratford, NJ, 08084, United States, 1 (856) 566-6789.
BMJ Open
September 2024
Oncology, Kantonsspital St Gallen, St. Gallen, Switzerland.
Introduction: Patients with advanced cancer frequently suffer from chronic, severe disabling pain. Opioids such as morphine and fentanyl are commonly used to manage this pain. Transdermal drug delivery systems are important technologies for administering drugs in a non-invasive, continuous and controlled manner.
View Article and Find Full Text PDFJ Pain Symptom Manage
December 2024
Department of Medical Oncology (B.C.A., K.V., E.O.D.H., F.V.T., E.G., C.C.D.V.D.R., S.L.W.K., A.W.O., R.H.J.M.), Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Context: Subcutaneous (SC) administration of fentanyl allows for rapid dose titration to treat urgent cancer-related pain. After establishing the optimal fentanyl dose, patients typically rotate towards transdermal (TD) fentanyl patches. Continuing the SC fentanyl up to 12h after application of the patch led to elevated fentanyl concentrations and fentanyl-related toxicities.
View Article and Find Full Text PDFInt J Pharm
October 2024
HBN Research Institute and Biological Laboratory, Shenzhen Hujia Technology Co., Ltd., 518000 Shenzhen, Guangdong, China; State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, CAS Key Laboratory of Chemistry of Plant Resources in Arid Regions, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, 830011 Urumqi, Xinjiang, China; University of Chinese Academy of Sciences, 100049 Beijing, China. Electronic address:
J Opioid Manag
July 2024
Toronto Rehabilitation Institute, University Health Network, University of Toronto, Toronto, Canada.
Transitioning a patient with chronic pain from a fentanyl patch to a buprenorphine patch has not been well described in the literature. Even after a patient removes their fentanyl patch, the residual fentanyl in the skin continues to be absorbed for hours. Due to the risk of precipitated withdrawal when initiating buprenorphine, this transition is a more challenging opioid rotation to plan safely.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!